Neuromod Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
65
- Latest Deal Type
-
2ndary - Private
- Investors
-
11
Neuromod General Information
Description
Developer of a medical technology designed to stimulate progress through the design, clinical validation, and commercialization of neuromodulation technologies. The company utilizes bi-modal neuromodulation to deliver effective targeted neurostimulation, enabling patients to take control of their treatment by adopting targeted therapies that integrate seamlessly into a modern lifestyle.
Contact Information
Website
www.neuromod.comCorporate Office
- Unit J, Digital Court, The Digital Hub
- Rainsford Street
- Dublin D08 R2YP
- Ireland
Corporate Office
- Unit J, Digital Court, The Digital Hub
- Rainsford Street
- Dublin D08 R2YP
- Ireland
Neuromod Timeline
Neuromod Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 14. Later Stage VC | 24-Jun-2026 | Completed | Generating Revenue | |||
| 13. Later Stage VC (Series B) | 11-Mar-2025 | Completed | Generating Revenue | |||
| 12. Later Stage VC | 26-Mar-2024 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series B2) | 12-Apr-2023 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 07-Nov-2022 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B) | 12-Oct-2020 | Completed | Generating Revenue | |||
| 8. Debt - General | 20-Sep-2019 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 25-Jul-2018 | $1.4M | $12.9M | Completed | Generating Revenue | |
| 6. Later Stage VC | 04-Dec-2017 | $1.88M | $11.5M | Completed | Generating Revenue |
Neuromod Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 Prefernce | ||||||||
| Series B2 Prefernce | ||||||||
| Series B Preference | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 7,633 | $0.000105 | $27.56 | $27.56 | 1x | $27.56 | 2.1% | |
| Ordinary | 12,260 | $0.000105 | $27.45 | $27.45 | 1x | $27.45 | 3.37% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Neuromod Comparisons
Industry
Financing
Details
Neuromod Competitors (22)
One of Neuromod’s 22 competitors is Curonix, a Private Equity-Backed company based in Pompano Beach, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Curonix | Private Equity-Backed | Pompano Beach, FL | ||||
| Neuspera | Venture Capital-Backed | San Jose, CA | ||||
| Salvia BioElectronics | Venture Capital-Backed | Eindhoven, Netherlands | ||||
| Mainstay Medical | Venture Capital-Backed | San Diego, CA | ||||
| CathVision | Venture Capital-Backed | Copenhagen, Denmark |
Neuromod Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neuromod Patents
Neuromod Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016354893-A1 | An apparatus and method for treating a neurological disorder of the auditory system | Active | 17-Nov-2015 | ||
| AU-2016354893-B2 | An apparatus and method for treating a neurological disorder of the auditory system | Active | 17-Nov-2015 | ||
| AU-2016358254-A1 | An apparatus and method for treating a neurological disorder of the auditory system | Active | 17-Nov-2015 | ||
| AU-2016358254-B2 | An apparatus and method for treating a neurological disorder of the auditory system | Active | 17-Nov-2015 | ||
| CA-3005662-A1 | An apparatus and method for treating a neurological disorder of the auditory system | Active | 17-Nov-2015 | A61B5/128 |
Neuromod Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neuromod Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| British Standards Institution | Corporation | Minority | ||
| Byrne Wallace Shields | Corporation | Minority | ||
| Shay Glenn | Corporation | Minority | ||
| Tomkins | Corporation | Minority | ||
| XB Ventures | Venture Capital | Minority |
Neuromod FAQs
-
When was Neuromod founded?
Neuromod was founded in 2010.
-
Where is Neuromod headquartered?
Neuromod is headquartered in Dublin, Ireland.
-
What is the size of Neuromod?
Neuromod has 65 total employees.
-
What industry is Neuromod in?
Neuromod’s primary industry is Monitoring Equipment.
-
Is Neuromod a private or public company?
Neuromod is a Private company.
-
What is Neuromod’s current revenue?
The current revenue for Neuromod is .
-
How much funding has Neuromod raised over time?
Neuromod has raised $71.7M.
-
Who are Neuromod’s investors?
British Standards Institution, Byrne Wallace Shields, Shay Glenn, Tomkins, and XB Ventures are 5 of 11 investors who have invested in Neuromod.
-
Who are Neuromod’s competitors?
Curonix, Neuspera, Salvia BioElectronics, Mainstay Medical, and CathVision are some of the 22 competitors of Neuromod.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
